Understanding functional status in people with interstitial lung disease
Official title: LetS Get fUnctional! FuNctional Status in pEople With intersTitial Lung Disease - the SUNSET Study
Run by Aveiro University · NCT06317831 · Data updated 2026-11-12
This study is trying to understand how interstitial lung disease affects people's daily activities and overall health, while also looking at what factors might make it worse.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Aveiro University Academic / other |
| Locations | 1 site (Aveiro) |
| Status | Recruiting |
| Started | April 1, 2024 |
| Main results expected | December 30, 2027 |
| Study ends | July 30, 2028 |
| Registry record updated | April 30, 2024 |
| Trial ID | NCT06317831 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older who have been diagnosed with any type of interstitial lung disease and are fluent in Portuguese.
✕Probably not a fit
Patients with other respiratory diseases, significant cognitive impairment, or other serious health conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to characterize the functional status of individuals with interstitial lung disease (ILD) and explore the factors contributing to its decline. It will assess the measurement properties of functional status instruments and gather participants' perspectives through interviews. The study also seeks to track the progression of functional status in ILD patients and develop a multidimensional index to predict mortality based on functional status parameters. Participants will be recruited from several hospitals in Portugal, focusing on a comprehensive assessment of their clinical and sociodemographic characteristics.
Why it matters
Potential benefit: If successful, this study could lead to improved patient-centered care and better management strategies for individuals with interstitial lung disease.
How similar studies have gone: Other studies have recognized the importance of functional status in ILD, but this specific approach to characterizing and predicting outcomes is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥18 years * Diagnosed with any type of ILD * Fluent in Portuguese * Able to provide informed consent. Exclusion Criteria: * Other respiratory diseases * A history of acute cardiac/respiratory condition in the previous month * Present signs of cognitive impairment * Significant cardiovascular, neurological and/or musculoskeletal disease that may limit their participation * Current neoplasia * Other autoimmune diseases (aside from ID).
Where it's running
-
University of Aveiro
Aveiro, Portugal Recruiting
Study contacts
- Principal investigator: Alda S. Marques, PhD — School of Health Sciences of the University of Aveiro (ESSUA)
- Study coordinator: Alda S. Marques, PhD
- Email: amarques@ua.pt
- Phone: 00351 234 372 462
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Home-based pulmonary rehabilitation for interstitial lung disease
This study tests a 6-week home-based pulmonary rehabilitation program to see if it improves breathing, exercise ability, and quality of life for people with fibrotic interstitial lung disease in India.
-
Photon-counting CT vs standard HRCT to help diagnose IPF and other ILDs
This study tests whether photon-counting CT can improve identifying IPF and other ILDs compared with standard HRCT for patients discussed in multidisciplinary teams.
-
Nerandomilast for fibrosing interstitial lung disease at risk of progression
This trial tests whether nerandomilast can help adults with fibrosing interstitial lung disease who are at risk of their disease getting worse.
-
Nerandomilast to slow lung changes in people with a family history of pulmonary fibrosis
This trial tests whether taking nerandomilast can slow early lung scarring in people aged 40 and older who have a first-degree relative with pulmonary fibrosis and CT evidence of interstitial lung abnormalities.
-
Ultra‑high‑resolution CT to look for lung and heart damage in progressive interstitial lung disease
This project will use advanced multidimensional CT scans to see if one noninvasive test can measure both lung fibrosis and early heart involvement in adults with progressive or long‑standing interstitial lung disease.
-
Evaluating a new CAR T cell therapy for systemic sclerosis
This study is testing a new CAR T cell therapy to see if it can help people with systemic sclerosis feel better and manage their symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.